The Society for Clinical Research Sites (SCRS) announced that StudyKIK has joined the organization as a Global Impact Partner (GIP). SCRS’ GIP Program provides an opportunity for sponsors, CROs, and solution providers to engage with SCRS and its members. Becoming a GIP demonstrates StudyKIK’s commitment to clinical research sites, their desire to develop a deeper understanding of the needs of sites, and contribute to the development and implementation of solutions in the marketplace.
"StudyKIK has believed in SCRS and the vision Christine Pierre founded the organization on, which is to be the unified voice for all research sites, since its inception," said the company's president and co-founder, Matt Miller. "We started StudyKIK with the same vision by building tools to empower sites to succeed in patient recruitment. Becoming an SCRS Global Impact Partner strengthens our commitment to supporting research sites and connecting patients to clinical trials."
“By joining SCRS as a GIP, StudyKIK has demonstrated their commitment to a strong and unified site community,” said SCRS president Casey Orvin. “StudyKIK has had a consistent presence at SCRS’ Site Solutions Summits throughout the years, and we are looking forward to expanding our engagement with the company through the GIP program.”
For more information, visit www.MySCRS.org
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Fast Tracks Johnson & Johnson’s Nipocalimab for Fetal Neonatal Alloimmune Thrombocytopenia
March 27th 2024Johnson & Johnson is moving forward with a pair of Phase III trials of nipocalimab to reduce the risk of fetal neonatal alloimmune thrombocytopenia in alloimmunized pregnant patients.